The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

PDL BioPharma Inc

Nasdaq: PDLI
Last

(U.S.) $2.27

Today's change-0.04 -1.73%
Updated February 17 4:00 PM EST. Delayed by at least 15 minutes.
 

PDL BioPharma Inc

Nasdaq: PDLI
Last

(U.S.) $2.27

Today's change-0.04 -1.73%
Updated February 17 4:00 PM EST. Delayed by at least 15 minutes.

PDL BioPharma Inc down (U.S.)$0.04

PDL BioPharma Inc closed sharply lower Friday, dropping (U.S.)$0.04 or 1.73% to (U.S.)$2.27. Over the last five days, shares have gained 0.44% and 7.08% year to date. Shares have underperformed the S&P 500 by 46.86% during the last year.

Key company metrics

  • Open(U.S.) $2.31
  • Previous close(U.S.) $2.31
  • High(U.S.) $2.32
  • Low(U.S.) $2.25
  • Bid / Ask(U.S.) $2.21 / (U.S.) $2.35
  • YTD % change+7.08%
  • Volume1,726,851
  • Average volume (10-day)1,570,183
  • Average volume (1-month)1,980,112
  • Average volume (3-month)2,325,528
  • 52-week range(U.S.) $1.93 to (U.S.) $3.84
  • Beta0.60
  • Trailing P/E2.14×
  • P/E 1 year forward4.18×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $1.06
Updated February 17 4:00 PM EST. Delayed by at least 15 minutes.
S&P TSX0.16%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2016Q2/2016Q1/2016Q4/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015
Revenue5421103178
Total other revenue--------
Total revenue5421103178
Gross profit--------
Total cost of revenue--------
Total operating expense21101010
Selling / general / administrative1071013
Research & development2------
Depreciation / amortization6------
Interest expense (income), net operating--------
Unusual expense (income)13---2
Other operating expenses, total2------
Operating income331193168
Interest income (expense), net non-operating-5-4-5-5
Gain (loss) on sale of assets--------
Other--------
Income before tax28789163
Income after tax14456101
Income tax, total1433362
Net income14456101
Total adjustments to net income--------
Net income before extra. items14456101
Minority interest0------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items14456101
Inc. avail. to common incl. extra. items14456101
Diluted net income14456101
Dilution adjustment--------
Diluted weighted average shares164164164165
Diluted EPS excluding extraordinary itemsvalue per share0.080.030.340.61
Dividends per sharevalue per share0.000.050.050.15
Diluted normalized EPSvalue per share0.090.040.340.60